New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 29, 2013
05:57 EDTONTXOnconova Therapeutics upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Onconova Therapeutics citing a favorable risk/reward following the recent pullback in shares. Citi lowered its price target for the stock to $27 from $30.
News For ONTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
10:33 EDTONTXOnconova to host analyst meeting
Subscribe for More Information
December 7, 2014
19:49 EDTONTXOnconova announces data from trials of rigosertib in myelodysplastic syndromes
Onconova Therapeutics announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes, MDS, at the 56th American Society of Hematology Annual Meeting in San Francisco, California, December 6-9. Three presentations from Dr. Guillermo Garcia-Manero, Dr. Lewis R. Silverman and Dr. Ghulam Mufti provided details of Phase 3 results from the ONTIME study of IV rigosertib in higher risk MDS. "The ONTIME pivotal trial with IV rigosertib was the first randomized, controlled clinical trial in higher risk MDS patients who had progressed on, failed to respond to, or relapsed after prior therapy with hypomethylating agents, HMAs," said Guillermo Garcia-Manero, M.D., lead investigator and Chief, Section of Myelodysplastic Syndromes, at the University of Texas MD Anderson Cancer Center. "Although the trial did not achieve its primary endpoint, rigosertib was found to improve overall survival in multiple patient subgroups, which represent a substantial proportion of MDS patients with the highest levels of unmet medical need. This group included patients who had progressed on or failed to respond to previous treatment with hypomethylating agents, as well as patients in the Revised International Prognostic Scoring System Very High Risk category, and patients with certain karyotypic abnormalities, such as, monosomy 7, del7q and trisomy 8. Patients in these subgroups have a very poor prognosis, and currently there is no approved drug available to treat their disease once they have failed HMA therapy."
16:33 EDTONTXOnconova presents data from study combining rigosertib and azacitidine
Onconova Therapeutics announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes, MDS, and non-proliferative acute myeloid leukemia, AML, at the 56th American Society of Hematology Annual Meeting in San Francisco, California, December 6-9. Based on synergistic anti-leukemic activity of the combination of rigosertib and azacitidine demonstrated in non-clinical studies, an exploratory, dose-range finding study was conducted at Mount Sinai Medical Center and the MD Anderson Cancer Center. "In this first-in-man Phase 1 trial, the combination of oral rigosertib and azacitidine was safely administered to patients with MDS or non-proliferative AML. Importantly, the addition of oral rigosertib to the standard dose of azacitidine did not worsen the adverse event profile compared to that reported for azacitidine alone," said Lewis R. Silverman, M.D., lead investigator and Associate Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai. "Furthermore, the rate of response observed in the Phase 1 portion of the study is promising and has led to the Phase 2 portion of this trial, which is now open at trial sites in the U.S. and Europe."
14:10 EDTONTXAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use